Stay updated with breaking news from Windlass biotech. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Five such companies which have firmed up their initial public offering (IPO) plans are Glenmark Lifesciences, a fully-owned arm of Glenmark Pharmaceuticals, the city-based bulk drugs firm Supriya Lifesciences, drug formulations firm Windlass Biotech, Bain Capital-backed Emcure Pharma and CX Partners-funded Veeda Clinical Research. According to investment-bankers, they are planning to mop up over Rs 7,000 crore in primary share sales. ....
IPO fever subsides, index dips 4% deccanchronicle.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from deccanchronicle.com Daily Mail and Mail on Sunday newspapers.
Asian peers opened lower as concerns over rising coronavirus cases in Japan continued to weigh on the market. South Korean and Thai stock markets remained shut on Monday. MSCI s broadest index of Asia-Pacific shares outside Japan s Nikkei tanked 1.35 per cent. ....
Windlas Biotech IPO oversubscribed 22.46 times on closing day business-standard.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from business-standard.com Daily Mail and Mail on Sunday newspapers.
New Delhi: It continues to rain IPOs this monsoon season. Dalal Street is all set to see as many as four IPOs hitting the market this week. They include Krsnaa Diagnostics, Devyani International, Exxaro Tiles and Windlas Biotech, which are going to raise close to Rs 3,614 crore between August 4 and 6. Companies are rushing to the primary market to make best of the excessive liquidity and investor optimism. But with four issues opening on the same day, investors who have limited capital to deploy, are in a dilemma as to what to pick and what not. Arijit Malakar, Head of Research (Retail) at Ashika Stock Broking, said investors should ride the ongoing momentum in the primary market as the buoyancy is likely continue. ....